What are the chances of DLBCL recurring after treatment?
DLBCL can return after successful treatment, with about 30 to 40 percent of people experiencing relapse within two years of finishing treatment. The risk is highest during this two-year window, known as an early relapse.
If you stay in remission beyond two years Show Full Answer
What are the chances of DLBCL recurring after treatment?
DLBCL can return after successful treatment, with about 30 to 40 percent of people experiencing relapse within two years of finishing treatment. The risk is highest during this two-year window, known as an early relapse.
If you stay in remission beyond two years, your chances of relapse decrease significantly. Research shows that for those who remained cancer-free for two years:
* 6.9 percent relapsed after three years
* 9.3 percent relapsed after five years
* 10.3 percent relapsed after eight years
The longer you stay in remission, the lower your risk of DLBCL returning.
Your initial response to treatment matters. About 75 percent of people achieve complete response after R-CHOP treatment, which comes with a lower relapse rate. Those who only achieve partial response face higher risks.
Males may have slightly higher relapse rates and worse outcomes compared to females. However, many factors influence your individual risk, including your age, overall health, and how widespread the lymphoma was initially. If DLBCL does relapse, treatment options are available. Your oncologist may recommend:
* Second-line chemotherapy (like bendamustine or gemcitabine, possibly with rituximab)
* CAR T-cell therapy (such as Kymriah or Yescarta)
* Bone marrow transplant (autologous or allogeneic)
* Bispecific antibodies (like Epkinly or Columvi for certain DLBCL subtypes)
* Clinical trials for new immunotherapies
Keep all your follow-up appointments and contact your oncology team right away if you notice symptoms like swollen lymph nodes or other concerning changes. Early detection can help you get treatment sooner.
November 15, 2025